Fli1 is a member of the Ets family of transcription factors and is preferentially expressed in hematopoietic cell lineages. Its expression level is linked to the pathogenesis of lupus. In this study, we identified mechanisms involved in the transcriptional regulation of the mouse and human Fli1 promoters. We show that the Fli1 promoter is upregulated by Ets factors Ets1, Ets2, Fli1 and Elf1 either alone or in combination with GATA factors, but is inhibited by Tel. In vitro binding studies show that Elf1, Tel and Fli1 in T cells bind the three Ets-binding sites in the murine Fli1 proximal promoter. We identified transcription factorbinding sites in the human Fli1 promoter region that function in T cells in a similar manner to those in the mouse promoter. Furthermore, we show similar binding of Ets factors to the endogenous mouse and human Fli1 promoters in T cells and knocking down Ets1 results in an upregulation of Fli1 expression. Together, these results suggest that the human and mouse genes are regulated similarly and that Ets1 may be important in preventing the overexpression of Fli1 in T cells. This report lays the groundwork for identifying targets for manipulating Fli1 expression as a possible therapeutic approach.
Introduction
Fli1 is a member of the Ets family of transcription factors that share a highly conserved Ets DNA-binding domain and bind to Ets-binding sites (EBS) within target genes. First identified as a proto-oncogene, Fli1 is normally expressed in the hematopoietic tissues, as well as in the lung, heart and ovary. [1] [2] [3] [4] During lymphoid development, Fli1 is expressed highly in mature B cells, pre-T cells and resting, mature T cells. 5 Systemic lupus erythematosus is a prototypic autoimmune disease characterized by the production of autoantibodies, formation of immune complexes and subsequent deposition in target tissues, resulting in local inflammation and organ damage. 6 A key feature of lupus pathogenesis is aberrant activation and proliferation of lymphocytes and overexpression of transcription factors. 7 Fli1 is overexpressed in splenic T cells of lupusprone NZB/NZW f1 mice, the spleen of lupus-prone MRL/lpr mice and in PBMCs of systemic lupus erythematosus patients. 8, 9 When Fli1 is overexpressed in healthy, non-autoimmune-prone mice, they develop autoreactive lymphocytes, autoantibodies and an immune complex-mediated kidney disease similar to that observed in lupus-prone mice. 10 Interestingly, genetically lowering the levels of Fli1 by 50% in MRL/lpr lupusprone mice resulted in decreased autoantibody production, improved kidney disease and significantly prolonged survival showing an unequivocal association between Fli1 expression and lupus pathogenesis. 9 Therefore, understanding how the Fli1 gene is regulated will be important for determining how it becomes overexpressed in lupus.
Recently, we showed that activity of the mouse Fli1 (mFli1) promoter is regulated by four EBSs, a GATAbinding site and two STAT-binding sites within the proximal promoter in B and T cells. 11 We observed in splenic extracts that Elf1, Fli1 and Tel bind three of the EBSs in vitro. Together, with the fact that many Ets factors are coexpressed with Fli1 in lymphocytes, these studies indicated several Ets factors are likely important for regulating Fli1 transcription in lymphocytes. Although the mouse and human 5 0 upstream regions are highly homologous, especially within the distal and proximal promoters, the transcriptional regulation of the human Fli1 gene (hFli1) in lymphocytes has not been investigated.
To further our understanding of the mechanisms involved in regulating the expression of mouse and human Fli1 in lymphocytes, we identified cis-regulatory elements in the human Fli1 promoter and examined the binding of Ets and GATA factors to the endogenous mouse and human Fli1 promoters in T cells. We show that the same cis-regulatory elements within the proximal mouse promoter are present in the human promoter and function in a similar manner in T cells. We show that five different Ets factors can activate the Fli1 proximal promoter individually or in conjunction with GATA factors in an additive or synergistic manner. Importantly, we show similar binding of Ets factors Ets1, Ets2, Fli1 and Elf1 to the endogenous promoter of both human and mFli1 genes and show that lowering Ets1 levels results in an upregulation of Fli1 expression in T cells. This report furthers our knowledge of the mechanisms involved in the regulation of Fli1 expression and suggests that murine lymphocytes will be an important model for studying hFli1 dysregulation, as it relates to patients with systemic lupus erythematosus.
Results
The mouse and human Fli1 upstream regulatory regions are highly homologous as illustrated in Figure 1a . Sequence alignment was performed and percent homology was calculated using the mVISTA program of the VISTA family of tools developed and hosted by the Genomics Division of Lawrence Berkeley National Laboratory (Berkeley, CA, USA). 12 The VISTA map below the schematic of the regions illustrates the high percentage of homology between the mouse and human sequences in the exon 1b and exon 1 regions (Figure 1a) . Specifically, the distal and proximal promoters are 83 and 88% homologous, respectively, and 95% homologous in the region from À271 to À37. This homology suggests that they may be regulated in a similar manner. Cis-regulatory elements within the human À271 to À37 sequence were identified by scanning for known transcription factor-binding sites and comparing to the same region in the mFli1 gene (Figure 1b) . Putative binding sites analyzed include four EBS (EBS1-4), a GATA-binding site and two STAT-binding sites (STATa and STATb), all of which are nearly perfectly conserved in the mouse sequence (Figure 1b ). An additional putative STAT (STATc) site was identified, which is not present in the mouse promoter.
A human Fli1 promoter/reporter (P/R) construct containing the region from À1766 to À37 (equivalent to the mouse region of À1778 to À37) was amplified from genomic DNA and ligated into the pGL3Basic reporter vector. To define the sequences necessary to drive expression in T lymphocytes, successive deletions from the 5 0 end of the hFli1 sequence were generated using the À1766/À37 construct ( Figure 2a ) and transiently transfected into the Jurkat T cell line (Figure 2b ). Similar to the mouse promoter, sequences from À1766 to À502 were not required for promoter activity, deletion of sequences from À502 to À271 resulted in increased promoter activity, whereas deletion from À271 to À209 significantly decreased promoter activity (Figure 2b ). These results suggest the region between À271 and À209 contains regulatory elements necessary for promoter activity in T cells and the À502 to À271 region may contain a negative regulatory element, similar to results observed with the mouse promoter.
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To determine whether the regulatory elements, identified in Figure 1b , are important for human promoter activity in T cells, each binding site was mutated by site-directed mutagenesis within the À271/À37 P/R construct and transfected into the Jurkat T cell line. The mutations were identical to those generated in the mouse construct. 11 The EBS1 site is located adjacent to a GATA site, resulting in a possible GATA/EBS dual element. 13 Mutating the EBS1 site had little effect, whereas the GATA mutation resulted in a 40% decease in promoter activity (Figure 2c ). Interestingly, mutating both the GATA and EBS1 sites resulted in a 70% decrease in promoter activity, suggesting a cooperative dual element in the human Fli1 promoter. Mutations in either EBS2 or EBS3 resulted in a 60-70% decrease in promoter activity, whereas mutating EBS4 resulted in a 40% increase in promoter activity (Figure 2c) .
The STATa and EBS2 sites overlap and the EBS2 mutation may disrupt binding to the STATa-binding site as well. Therefore, a mutation in the STATa site was engineered to disrupt the binding of the STATa site and leave the EBS2 site intact. The STATa mutation resulted in a 2.5-fold increase in promoter activity (Figure 2c ), indicating that the STATa site is a negative regulatory element and the EBS2 is a positive regulatory element. A STATb mutation resulted in a slight decrease in activity. These results are similar to those observed in the mouse promoter in a murine T cell line, suggesting that all of the sites identified in the mouse are functional sites in the human promoter as well. 11 In the human promoter region, an additional putative STAT site (STATc) was identified, which is not present in the mouse promoter (Figure 1b) . Mutation of the STATc site resulted in a 1.5-fold increase in promoter activity, suggesting that it is a functional element (Figure 2c) . A second mutant of the STATc site, STATc h/m, was constructed. The STATc h/m mutation is a one base pair deletion converting the human sequence to match the mouse sequence. This mutation had no effect on promoter activity compared with the wild-type construct, showing that the STATc site does not require the deleted base pair and suggests that this site in the mouse promoter may be a functional STAT site. Together, these results suggest that the STATa and STATc sites are negative regulatory elements, whereas the STATb site acts as a weak positive regulatory element in T cells.
Fli1 is expressed highly in mature B cells and resting mature T cells along with at least seven other Ets factors. 5 To determine which coexpressed Ets factors transactivate from the four sites identified in the proximal promoter, co-transfection experiments with the mFli1 À271/À37 P/ R vector, and Ets expression vectors were performed in HeLa cells. HeLa cells express very low levels of most Ets factors, 14 reducing effects on the P/R construct by endogenous Ets expression. Cells were co-transfected with a constant amount of the mFli1 À271/À37 P/R vector and either an empty expression vector or increasing amounts of Ets1, Ets2, PU.1, Fli1, Elf1 or Tel expression vectors. Ets1, Ets2, PU.1, Fli1 and Elf1 all activated the promoter in a dose-dependent manner; however, Tel not only failed to stimulate, but inhibited the basal expression of the mFli1 À271/À37 P/R construct (Figure 3a) . Moreover, Tel inhibited Ets1, Ets2, Fli1 and Elf1 activation of the mouse promoter in a dosedependent manner (Figure 3b ). Similarly, Tel inhibited the activation of the human Fli1 À502/À37 and À271/ À37 P/R constructs by Ets1, Ets2, Fli1 and Elf1 (data not shown). Tel may be inhibiting transactivation of the Fli1 promoter by the other Ets factors through competition for binding to available EBS or by direct physical interaction, as Tel was shown to directly interact with Fli1 in 293 cells. 15 Through site-directed mutagenesis of each individual EBS, we showed that EBS1, 2 and 3 are positive regulatory elements and EBS4 is a negative regulatory element in the mouse 11 and human Fli1 promoters ( Figure 2 ). Co-transfection of Ets factors with the mFli1 À271/À37 construct containing a mutation in EBS1, 2 or 3 in HeLa cells resulted in slight decreases in the promoter activity compared with the wild-type P/R (data not shown). However, the differences were not Expression is presented relative to the P/R vector co-transfected with the empty expression vector pcDNA3, which was set to 1. (b) Expression is presented relative to the P/R vector cotransfected with Ets1, Ets2, Fli1 or Elf1, which was set to 1. Results are representative of at least three separate transfections. Student's t-test was used to compare relative expression to mFli1 À271/À37 P/R plus pcDNA3 (a) or mFli1 À271/À37 P/R plus Ets1, Ets2, Fli1 or Elf1 (b). P-values o0.05 were considered significant as indicated by (*). P/R, promoter/reporter. statistically significant, indicating that each of these factors is able to transactivate from any one of the three positive EBS. To determine precisely through which EBS each Ets factor may preferentially transactivate the Fli1 promoter, HeLa cells were co-transfected with the mFli1 À271/À37 P/R containing mutations within three of the four EBS, resulting in the availability of only one of the EBS (Figure 3c ). When only one positive EBS was available, transactivation of the mutated P/R construct by each Ets factor was markedly reduced compared with the wild-type P/R, indicating that the stimulation of the promoter by Ets1, Ets2, PU.1, Fli1 and Elf1 is dependent on the three positive EBS, EBS1, 2 and 3. Furthermore, these results suggest that the Ets factors are highly promiscuous and that binding and transactivation through the three positive EBS is additive and that all three sites are necessary for optimal promoter activity in this cellular context. GATA/EBS dual elements function cooperatively in the activation of other genes. 13, 16 To determine whether Ets and GATA proteins can synergistically activate the Fli1 promoter through the GATA/EBS1 dual element, the À271/À37 mFli1 P/R vector and expression vectors for Ets1, Ets2, PU.1, Fli1 and Elf1 were co-transfected into HeLa cells with increasing amounts of a GATA1 or 3 expression vector. A low level of 25 ng of each Ets factor, which has minimal effect on promoter activity alone, was used to observe any additive or synergistic effects in conjunction with the GATA factors. Results from these experiments showed that GATA1 and 3 alone activate the mFli1 promoter to a maximum of two-and three-fold, respectively (Figures 4a and b) . However, cotransfection of Ets1, Ets2 or Fli1 with increasing amounts of GATA1 resulted in a more than additive activation of the mFli1 promoter (Figure 4a ), suggesting synergistic activity. Synergistic activity was also observed with GATA3 and Ets1 or Ets2, but GATA3 had only an additive effect in conjunction with Fli1 (Figure 4b ). On the other hand, Elf1 synergized with GATA3, but had only a slight additive effect in conjunction with GATA1 (Figures 4a and b) . Neither GATA1 nor 3 could synergize in conjunction with PU.1. In fact, GATA3 inhibited PU.1 stimulation of the promoter (Figure 4b) . Interestingly, promoter activation by all of the Ets factors tested, except Elf1, in the presence of GATA3 decreased as GATA3 levels increased (Figure 4b ), indicating that Fli1 promoter activity may be sensitive to the precise levels of GATA3, the GATA factor, which is preferentially expressed in T cells. 17, 18 Although most of the Ets factors examined can stimulate the mFli1 promoter activity in HeLa cells, the dynamics in primary T cells, such as relative expression levels, availability of cofactors and/or availability of binding partners likely determine which Ets factor will bind and transactivate from a specific EBS. Previously, we showed that Elf1, Tel and Fli1 bind in vitro to EBS1, 2 and 3, respectively, in extracts from whole mouse spleen. 11 We further show here that this binding is mirrored specifically in primary murine T and B cells ( Figure 5 ). Binding of Elf1 to GATA/EBS1, Tel to EBS2 and Fli1 to EBS3 probes was identified by the disappearance or supershift of specific DNA-protein complexes following addition of Ets-specific antibodies in both B and T cell nuclear extracts from spleens of nonautoimmune-prone BALB/c mice. Similar results were observed in purified B and T cells from another nonautoimmune-prone strain, C57BL/6 (data not shown). Ets1 and Ets2 do not readily bind to DNA in vitro due to the presence of auto-inhibitory domains, 19 and proteins that bind a particular site in vitro may not preferentially bind the same site in vivo. Therefore, to identify the Ets factors that bind the Fli1 promoter in live T cells, in vivo binding assays using chromatin immunoprecipitation (ChIP) were performed in T cells with antibodies specific for various Ets factors. In primary, naive T cells from C57BL/6 mice, antibodies specific for Ets1, Ets2, Fli1 or Elf1 resulted in significant enrichment of the mFli1 proximal promoter compared with IgG, with Ets1 and Ets2 resulting in the greatest relative enrichment (Figure 6a ). ChIP assays were also performed in primary, naive T cells from C57BL/6 mice using antibodies against GATA1, 2 and 3 ( Figure 6c ). Although GATA1 and 3 can cooperatively activate the Fli1 promoter in conjunction with Ets1, Ets2, Elf1 and Fli1, no significant enrichment of the mFli1 promoter was observed with GATA1, 2 and 3 antibodies in naive T cells. These results were replicated in T cells from BALB/c mice (Figures 6b and d) , showing that the relative binding of Ets factors to the mFli1 promoter is not strain specific. As a negative control, all ChIP templates were used in PCR with primers specific for the exon 3 region of the murine Fli1 gene, which is located 75 kb downstream of the promoter, and not expected to bind Ets factors. No enrichment of exon 3 was observed with any of the antibodies used (data not shown).
To further determine whether the human and mouse genes are similarly regulated in T cells, in vivo binding of Ets factors to the human promoter was examined. ChIP assays were performed in the Jurkat T cell line using antibodies specific for various Ets factors. Antibodies specific for Ets1, Ets2, Fli1 and Elf1 resulted in significant enrichment of the human Fli1 proximal promoter compared with IgG (Figure 7a) . Overall, the relative amount of bound Ets factors to the human promoter region in human T cells in vivo was similar to that observed in the mouse promoter in mouse T cells in vivo with the exception of Elf1 (Table 1) . ChIP assays also were performed with the human promoter in Jurkat T cells using antibodies against GATA1, 2 and 3. As observed with the mouse promoter, no significant enrichment of the human promoter with GATA1, 2 or 3 antibodies was observed (Figure 7b) .
ChIP analysis showed that Ets factors bind the in vivo Fli1 promoter region in T cells from mouse and human. In both species, Ets1 antibodies resulted in the greatest enrichment of this region. To determine whether reducing the levels of Ets1 has an effect on Fli1 expression, RNA interference for Ets1 was performed. S1A T cells were transfected with shRNA plasmids specific for mouse Ets1 or a scrambled sequence. Transfection efficiency was determined to be B55% (data not shown). RNA and protein were prepared 24 and 48 h after transfection and subjected to real-time PCR and western blotting, respectively for verification of Ets1 knockdown. Owing to the low transfection efficiency of T cells, we observed only a 20% decrease in Ets1 message levels ( Figure 8 ) and protein levels (data not shown) compared with cells transfected with shRNA that scrambled negative control at both 24 h (Figure 8a ) and 48 h (Figure 8b ) post-transfection. Importantly, this reduction was reproducible and statistically significant at 24 h, and resulted in a reproducible and statistically significant T cell T cell T cell 2.1-fold increase of Fli1 message levels at 24 h (Figure 8a ). Fli1 expression also increased 1.3-fold at 48 h but did not reach statistical significance ( Figure 8b ). As an added control, message levels of Ets2 and Elf1, which are coexpressed with Fli1 in T cells, were measured in these samples. Reducing Ets1 had no significant effect on Ets2 and Elf1 message levels at 24 h (Figure 8a ) or 48 h (Figure 8b ) post-transfection, showing that reducing Ets1 expression had a specific effect on Fli1 message levels. Together, these results further support a role for transcriptional regulation of endogenous Fli1 by Ets factors in T lymphocytes.
Discussion
T lymphocytes are known to have a significant role in the pathogenesis of lupus 20 and it is clear that altering Fli1 expression has profound effects on the pathogenesis of lupus. [8] [9] [10] Identifying the mechanisms involved in controlling Fli1 expression in T lymphocytes may result in new avenues for treating autoimmune diseases like lupus. This report provides further description of the mechanisms involved in the transcriptional regulation of the mFli1 gene and the first description of mechanisms involved in the regulation of the human Fli1 gene in T lymphocytes.
The human and mouse Fli1 proximal promoters are 95% homologous within the À271/À37 region, the region we identified to contain optimal activity in T cells. We showed that the previously identified cis-regulatory elements in the À271/À37 region of the mouse promoter are functionally conserved in the human promoter and identified an additional STAT site that functions as a negative regulatory element. Previously, we showed Elf1, Tel and Fli1 binding to EBS1, 2 and 3, respectively, of the mFli1 promoter in nuclear extracts made from whole spleen. 11 Here, we confirmed this in vitro binding specifically in primary B and T cells. We also showed that Ets1, Ets2, PU.1, Elf1 and Fli1 itself, which are coexpressed with Fli1 in lymphocytes, could transactivate the murine Fli1 proximal promoter.
To confirm our in vitro results, we performed in vivo binding assays with the mouse and human promoters. We showed that Ets1, Ets2, Elf1 and Fli1 bind the endogenous Fli1 promoter in both human and mouse, suggesting that the genes are regulated in a similar manner. For purposes of discussion, we compared the levels of Ets1 to the other Ets factors bound to the mouse and human promoters in the in vivo binding studies (summarized in Table 1 ). The relative binding to the mouse promoter in BALB/c and C57BL/6 was nearly identical. In comparing the binding to the mouse and human promoters, both species showed relatively little binding of Tel compared with Ets1. However, we observed lower levels of Elf1 and increased levels of Ets2 relative to Ets1 in human cells compared with mice. Despite these subtle differences, the overall trend of associated Ets factors with the Fli1 promoter is similar in both human and mouse T cells, indicating a key role of the Ets transcription factor family in regulating Fli1 in T cells. Interestingly, Ets1 and Ets2 resulted in the greatest enrichment in both mouse and human, indicating that they may be key in vivo regulators of the Fli1 promoter in T cells. Ets1 may be a ubiquitous transactivator of Fli1, as it also has been implicated in regulating Fli1 expression in non-lymphoid tissues. 21 In light of recent studies, binding of Ets1 to the endogenous Fli1 promoter poses an interesting scenario. Ets1 knockout mice exhibit a lupus-like autoimmune phenotype. 22 These mice have an elevated proportion of T cells with an effector memory phenotype, similar to that observed in MRL/lpr lupusprone mice. 23 Together with the known overexpression of Fli1 in lupus mice, 8, 9 we hypothesize that the Ets1 knockout mouse phenotype may be due in part to the dysregulation of Fli1 expression in these mice. Loss of Ets1 may allow other Ets factors that are stronger transactivators to bind, leading to the overexpression of Fli1. This notion is further supported by our observation of increased transcription of Fli1 following RNA interference of Ets1 in S1A T cells.
The observed association of Elf1 with the Fli1 promoter in vivo is also of significant interest. Elf1 activation requires post-translational phosphorylation and glycosylation for nuclear transport and binding, which has been shown to be defective in T cells of lupus patients. 24 Our results suggest that Elf1 may be a key regulator of Fli1 expression in T cells and the Elf1 defect in human lupus may be one mechanism by which Fli1 becomes overexpressed in lupus T cells. Loss of Elf1 binding may allow other more potent Ets transactivators to bind, such as Fli1, leading to overexpression.
We showed in this study the relative association of Fli1 with its own promoter in both human and mouse T cells in vivo. Overexpression or ectopic expression of Fli1 has been observed to upregulate endogenous Fli1 expression and perturb normal lymphoid cell function and programmed cell death. 10 Previously, we showed that Fli1 can upregulate its own expression in a T cell line.
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Together with the activation of the Fli1 promoter by Fli1 itself observed in this study, these results suggest a potential positive feedback loop for Fli1 expression in T cells.
In contrast to the other Ets factors tested, Tel, which is also coexpressed with Fli1 in T lymphocytes, not only failed to transactivate the proximal promoter but also inhibited the basal expression of the promoter in HeLa cells. Tel also inhibited the stimulation of the promoter by Ets1, Ets2, Fli1 or Elf1, indicating that Tel may act as a negative regulator of Fli1 under certain cellular conditions. It was also noted that we observed no significant in vivo binding of Tel to the Fli1 promoter in human or mouse T cells. This conflicts with our previous observation in which overexpression of Tel resulted in an increase in endogenous Fli1 mRNA expression in a T cell line. 11 Tel is normally expressed at very low levels in both naive and activated T cells. Therefore, it is likely that overexpression of Tel in this cellular context could result in aberrant expression of Fli1, or Tel may be acting through an as yet unidentified EBS outside of the proximal promoter. Tel activity also may not be properly regulated in the T cell line used. In some cellular contexts, Tel must become sumoylated to act as a negative transcriptional repressor. 15, 25 Regardless, our results indicate very little association of Tel with the endogenous proximal promoter in primary naive T cells, indicating that Tel may only have a small role, if any, in Eluted chromatin from IPs was used in real-time PCR using primers specific for the human Fli1 promoter region in exon 1. Immunoprecipitations were performed on three sets of chromatin, represented as an average in graph, and PCR was run twice in triplicate for each set. Error bars represent s.e. Student's t-test was used to compare IPs with non-specific IgG. P-values o0.05 was considered significant as indicated by (*). IP, immunoprecipitation. Values are displayed as a ratio compared with mean bound Ets1 as observed in Figures 6 and 7 .
regulating Fli1 in naive T cells. However, based on the ability of Tel in primary T cell extracts to bind to the EBS2 site of the proximal promoter in vitro, we speculate that Tel may have a role in downregulating Fli1 when T cells become activated.
Competition for available EBS may result in changes in relative association of Ets factors to the proximal promoter depending on cellular environment or state of disease. Overall levels of promoter bound Ets factors or availability of binding partners and cofactors may also change during pathogenesis. For example, steric constraints resulting in antagonism between Ets and GATA factors at the Fli1 promoter where both factors engage the DNA simultaneously may occur. This scenario may have precedent. Traditional thinking was that GATA3 specifically drove T helper type 2 cell differentiation, but has now emerged as having multiple roles in T lymphocyte development. 26 How can this single transcription factor that is continuously expressed during T-cell development perform different functions has yet to be understood. Competition and collaboration with other factors like Ets1 and Ets2 may partially explain this phenomenon. Ets1 and Ets2 cooperate with GATA3 to activate the interleukin-5 gene in both T and myeloid cells. 27 In our current study, we observed Fli1 P/R transactivation by Ets1, Ets2, GATA3 or GATA1 individually, whereas synergistic transactivation resulted when these Ets and GATA factors were co-transfected. In naive T cells, we were unable to pull down the in vivo Fli1 promoter region with antibodies against GATA factors, indicating that GATA/Ets cooperation may not be important in this cellular context. GATA3 expression increases in activated T cells following immune stimuli. Therefore, GATA/Ets interactions may then become relevant in regulating the Fli1 promoter. 28 Thus, balanced expression and activity of GATA and Ets factors could selectively promote Fli1 expression in certain physiological states.
We hypothesize that precise levels of Ets factors are important in regulating Fli1 expression. Loss of a single Ets factor could change the dynamics of Ets DNA binding, and/or interactions with binding partners or cofactors that may lead to an increase, as seen in lupus T cells, or a decrease, as seen in fibrosis, of Fli1 expression and contribute to pathogenesis. Future studies will be aimed at dissecting the dynamics of Ets factor binding and levels in regulating Fli1 and to identify potential targets and/or biomarkers for these diseases.
Materials and methods
Mice All mice were maintained at the Ralph H Johnson VAMC Animal Care Facility (Charleston, SC, USA) and experiments were approved by the Institutional Animal Care and Use Committee. BALB/c and C57BL/6 mice were purchased from Jackson Laboratory, Bar Harbor, ME, USA. Spleens were harvested from killed mice. Splenic T and B lymphocytes were isolated by negative selection using the MACS T Cell and B Cell Isolation Kits (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's recommendations. Cell populations were analyzed by flow cytometry and found to be 85-95% pure.
Cell lines
HeLa cells were maintained in DMEM/F12 (50/50) supplemented with 5% fetal bovine serum. S1A.TB.4.8.2 (S1A) and Jurkat T cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum. 
Plasmids and transfections
Cloning of the Fli1 promoter sequence and all mFli1 P/R constructs were described previously. 11 pcDNAPU.1 was constructed by moving the PU.1 cDNA from pCMV5PU.1 into the pcDNA3 vector. pcDNAEts1, pcDNAEts2 and pCMV5PU.1 expression vectors were obtained from Dr Angie Rizzino (University of Nebraska Medical Center, Omaha, NE, USA). pcDNAFli1, pcDNAElf1 and pSG5GATA1 were obtained from Dr Dennis Watson (Medical University of South Carolina, Charleston, SC, USA), and pcDNATel and pCTAPGATA3 expression vectors were obtained from Dr Maria Trojanowska (Medical University of South Carolina, Charleston, SC, USA).
The sequence encompassing the human Fli1 proximal and distal promoter regions from À1766 to À37 (equivalent to the mouse region of À1778 to À37) was amplified from genomic DNA from an unaffected control in the Carolina Lupus Study cohort. The amplified product was ligated into the SmaI and BglII sites of the pGL3 Basic luciferase reporter vector (Promega, Madison, WI, USA) to generate the pGL3 hFli1 À1766/À37 P/ R construct. Deletions of the 5 0 end of the À1766/À37 sequence were generated by restriction enzyme digestion and religation at À1265 (MluI) and À505 (NheI) to generate pGL3 hFli1 À1265/À37 and pGL3 hFli1 À502/ À37 P/R constructs. The pGL3 hFli1 À271/À37 and pGL3 hFli1 À209/À37 P/R constructs were generated by PCR using primers to amplify the entire pGL3 hFli1 À1766/À37 plasmid excluding the regions from À1766 to À271 and À1766 to À209, respectively.
Mutations within the four EBS, the GATA site and two of the three STAT sites (a and b) of the pGL3 hFli1 À271/ À37 construct were generated by site-directed mutagenesis as described previously, incorporating the same base pair changes as described for the mFli1 P/R mutant constructs. 11 The STATc and h/m STATc mutations were generated by site-directed mutagenesis as described previously. 11 The STATc mutant contains a two base pair change within the STATc site that destroys a TfiI site used for screening. The h/mSTATc mutant contains a deletion of the 'T' not present in the mouse sequence and also destroys a TfiI site used for screening. Two clones of each construct were generated and tested in transfections. Deletions and mutations were confirmed by direct sequencing of all clones. All transfection of human clones were performed in duplicate in the Jurkat T cell line with Fugene reagent (Roche, Basel, Switzerland) according to manufacturer's instructions. The mFli1 À271/À37 P/R construct or human Fli1 À502/À37 and À271/À37 P/R constructs were co-transfected into HeLa cells with either an empty expression vector (pcDNA3) or pcDNAEts1, pcDNAEts2, pcDNAFli1, pcDNAElf1, pcDNATel or pcDNAPU.1 expression vectors and/or pSG5GATA1 or pCTAPGATA3 expression vectors in the amounts indicated in the figures. All transfections were performed in duplicate with Fugene reagent (Roche) according to manufacturer's instructions. Luciferase activity was measured and normalized to expression from a co-transfected renilla luciferase expression vector (Promega). Total amount of plasmid was kept constant. Expression is presented relative to the P/R vector cotransfected with the empty vector, which was set to 1.
SureSilencing shRNA plasmids targeting mouse Ets1 were purchased from SABiosciences (Frederick, MD, USA). Clones were expanded and tested according to the manufacturer's instructions. A total of 4 mg of the shRNA-Ets1 plasmids or scrambled control plasmids were transiently transfected into 1 Â 10 6 cells of the S1A mouse T cell line using an Amaxa nucleofection device (Lonza Group Ltd, Switzerland), program T-16, according to the manufacturer's instructions. Cells were cultured as described above for 24 and 48 h before extracting total RNA. Real-time PCR was performed as described below.
Nuclear extracts, electrophoretic mobility shift assays Nuclear extracts were prepared from whole spleen, primary T cells and primary B cells from 12-week-old BALB/c or C57BL/6 mice or from the S1A T cell line, as indicated in figure legends, using the NE-PER kit (Pierce/Thermo Scientific, Rockford, IL, USA). Extracts were incubated with fluorescently labeled probes consisting of synthesized, annealed oligos containing murine sequences surrounding the cis-regulatory elements indicated, and separated by electrophoresis on polyacrylamide gels, as described previously. 11 Binding was visualized by scanning the gels on the Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE, USA). Specific factors bound to the cis-regulatory elements in the electrophoretic mobility shift assays were identified by the addition of antibodies against the Ets transcription factors indicated in the figures. Antibodies were added to the binding reaction before addition of the probe.
ChIP
Nuclear proteins were crosslinked to chromatin by addition of 1% formaldehyde to the cells for 10 min. Chromatin from lysed cells was sheared to an average length of 500 bp using a Branson-450 Sonifier (Branson Ultrasonics Corp., Danbury, CT, USA) and pre-cleared with blocked Protein A Dynabeads (Invitrogen/Life Technologies, Carlsbad, CA, USA). Immunoprecipitations were performed using antibodies against the factors indicated in figures. IgG was used as a negative control. All antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Antibody/chromatin complexes were then bound to Protein A Dynabeads and washed on a magnetic separation stand. Eluted complexes were decrosslinked, proteins degraded with Proteinase K solution (Shelton Scientific-IBI, Peosta, IA, USA) and immunoprecipitated DNA was purified with a PCR Purification Kit (Qiagen, Hilden, Germany). 0 -TGGACTGCAGCGTTAGC-3 0 and hEx3ChIPDn 5 0 -TGGTCATGTTGGGAGGA-3 0 . PCR was quantified on a BioRad MyiQ real-time PCR SYBR Green detection system (BioRad, Hercules, CA, USA) in triplicate in two independent runs. Fold enrichment was compared with immunoprecipitations with IgG, which was set to 1.
Real-time PCR
Purified RNA from S1A T cells was extracted using Qiagen's RNeasy kit. cDNA was prepared using iScript cDNA synthesis kit (BioRad). The cDNA served as a template for real-time PCR using iQ SYBR Green Supermix (BioRad) to measure Ets1, Fli1, Ets2, Elf1 and GAPDH (glyceraldehyde 3-phosphate dehydrogenase) expression. Primers used to measure mouse Ets1, Ets2 and Elf1 were described previously in Landry et al. 29 and primers used to measure mFli1 and GAPDH were described previously in Nowling et al. 11 The threshold cycle number (Ct) for each gene in each sample was measured using the MyiQ Real-time PCR Detection system and software (BioRad). Relative expression levels were calculated using the Gene Expression Macro software (BioRad). Briefly, Ct values were normalized to GAPDH expression for each sample by subtracting the GAPDH Ct from the Fli1, Ets1, Ets2 or Elf1 Ct (gene of interest) to give the DCt. A relative fold change was calculated using the calculation 2 (DDCt) , where DDCt is the difference between the DCt of the sample and the DCt of the reference sample, which was set to 1. The cells transfected with the scrambled shRNA was used as the reference sample. Message levels for all genes were measured in triplicate within the same cDNA sample and two sets of cDNA were prepared from each RNA sample.
